Lantheus Holdings, parent company of Lantheus Medical Imaging, along with its subsidiary Progenics Pharmaceuticals, announced their prostate-specific membrane antigen (PSMA) product candidates will be featured in three presentations at the upcoming 2021 American Society for Clinical Oncology Genitourinary (ASCO GU) virtual meeting.
Two abstracts cover the firm's PET/CT imaging agent for prostate cancer, PyL, and the third abstract relates to Lantheus' radiopharmaceutical therapeutic for metastatic castration-resistant prostate cancer, 1095.
